Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study
| Autor: | Tetsuo Iida, Dmitry M. Yaranov, Latonya Been, Masaaki Tokuda, Jose Rivas Rios, Dominick J. Angiolillo, Yuma Tani, Noriko Hayashi, Arshag D. Mooradian, Fabiana Rollini, Andrea Rivas, Francesco Franchi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
Sucrose medicine.medical_specialty 030309 nutrition & dietetics Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Fructose Placebo Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine nutrients Diabetes mellitus Internal medicine medicine Humans Insulin Ingestion Prospective Studies Sugar 0303 health sciences Cross-Over Studies business.industry medicine.disease RC648-665 Crossover study Glucose Endocrinology Postprandial type 2 chemistry diabetes mellitus dietary sugars Clinical care/Education/Nutrition business |
| Zdroj: | BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021) BMJ Open Diabetes Research & Care |
| ISSN: | 2052-4897 |
| Popis: | IntroductionCurrent dietary guidelines recommend limiting sugar intake for the prevention of diabetes mellitus (DM). Reduction in sugar intake may require sugar substitutes. Among these, D-allulose is a non-calorie rare monosaccharide with 70% sweetness of sucrose, which has shown anti-DM effects in Asian populations. However, there is limited data on the effects of D-allulose in other populations, including Westerners.Research design and methodsThis was a prospective, randomized, double-blind, placebo-controlled, crossover study conducted in 30 subjects without DM. Study participants were given a standard oral (50 g) sucrose load and randomized to placebo or escalating doses of D-allulose (2.5, 5.0, 7.5, 10.0 g). Subjects crossed-over to the alternate study treatment after 7–14 days of wash out. Plasma glucose and insulin levels were measured at five time points: before and at 30, 60, 90 and 120 min after ingestion.ResultsD-allulose was associated with a dose-dependent reduction of plasma glucose at 30 min compared with placebo. In particular, glucose was significantly lower with the 7.5 g (mean difference: 11; 95% CI 3 to 19; p=0.005) and 10 g (mean difference: 12; 95% CI 4 to 20; p=0.002) doses. Although glucose was not reduced at the other time points, there was a dose-dependent reduction in glucose excursion compared with placebo, which was significant with the 10 g dose (p=0.023). Accordingly, at 30 min D-allulose was associated with a trend towards lower insulin levels compared with placebo, which was significant with the 10 g dose (mean difference: 14; 95% CI 4 to 25; p=0.006). D-allulose did not reduce insulin at any other time point, but there was a significant dose-dependent reduction in insulin excursion compared with placebo (p=0.028), which was significant with the 10 g dose (p=0.002).ConclusionsThis is the largest study assessing the effects of D-allulose in Westerners demonstrating an early dose-dependent reduction in plasma glucose and insulin levels as well as decreased postprandial glucose and insulin excursion in subjects without DM. These pilot observations set the basis for large-scale investigations to support the anti-DM effects of D-allulose.Trial registration numberNCT02714413. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|